Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 26, 2026, 3:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Intervention: Placebo for Glimepiride Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, PF-04937319 10 mg, PF-04937319 50 mg, PF-04937319 100 mg, Glimepiride; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 23
States / cities: Roseville, California • San Diego, California • Walnut Creek, California + 17 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: liraglutide, glimepiride, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 746 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 102
States / cities: Concord, California • Escondido, California • Fullerton, California + 83 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Bexagliflozin, Placebo for Bexagliflozin, Glimepiride, Placebo for Glimepiride; Drug
Lead sponsor: Theracos; Industry
Eligibility: 18 Years and older
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 11
States / cities: Birmingham, Alabama • Huntington Park, California • Los Angeles, California + 8 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Ranolazine, Placebo, Glimepiride, Diet, Exercise; Drug · Behavioral
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 431 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 46
States / cities: Mesa, Arizona • Tucson, Arizona • Pine Bluff, Arkansas + 39 more

Conditions: Diabetes Mellitus
Interventions: Pioglitazone, Glimepiride; Drug
Lead sponsor: Takeda; Industry
Eligibility: 45 Years to 85 Years
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Type 2 Diabetes Mellitus
Interventions: JTT-851, Glimepiride, Placebo for Active, Placebo for comparator; Drug
Lead sponsor: Akros Pharma Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 79
States / cities: Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 76 more

Conditions: Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Interventions: Canakinumab 150 mg, Placebo to Canakinumab; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 11
States / cities: Los Angeles, California • Santa Ana, California • Spring Valley, California + 7 more

Conditions: Pharmacokinetics
Interventions: TAK-875 and Glimepiride; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 68 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: Linagliptin, Linagliptin Placebo, Glimepiride; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 15
States / cities: Birmingham, Alabama • Peoria, Arizona • Greenbrae, California + 10 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Placebo, Dulaglutide, Glimepiride; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 6
States / cities: Chino, California • Miami, Florida • St Louis, Missouri + 3 more

Conditions: Diabetes Mellitus, Type 2
Interventions: TAK-875, TAK-875 Placebo, Glimepiride; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 38
States / cities: Muscle Shoals, Alabama • Phoenix, Arizona • Fresno, California + 35 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo identical to BI 1356 5mg, Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg, BI 1356, Glimepiride; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 23
States / cities: Tempe, Arizona • Chula Vista, California • Los Angeles, California + 19 more

Conditions: Diabetes Mellitus, Type 2
Interventions: TAK-875, Glimepiride, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 64
States / cities: Birmingham, Alabama • Hoover, Alabama • Tucson, Arizona + 61 more

Conditions: Type 2 Diabetes, Cardiovascular Disease
Interventions: Sitagliptin, Glimepiride, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 22 Years to 70 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Aurora, Colorado

Search by objective public record fields.

Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin

To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c

Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease.

Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus

To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies

TAK-875 Glimepiride Drug-Interaction Study

A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate

Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)

Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes

Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes

Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus

Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes